icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Establishment of persistent functional remission of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 1.5 -2 year follow-up results from the REP 301-LTF study
 
 
  Reported by Jules Levin
EASL 2018 April 11-15 Paris France
 
M. Bazinet1, V. Pantea2, V. Cebotarescu2, L. Cojuhari2, P. Jimbei3, A. Krawczyk4, A. Vaillant1
 
1.Replicor Inc. Montreal, Canada
 
2.Department of Infectious Diseases, Nicolae TestemitanuState University of Medicine and Pharmacy, Chisinau, Republic of Moldova
 
3.TomaCiorbaInfectious Clinical Hospital, Chisinau, Republic of Moldova.
 
4.UniversitätsklinikumEssen, Institute for Virology, Essen, Germany.

0521181

0521182

0521183

0521184

0521185

0521186

0521187

0521188

0521189

05211810

05211811

05211812

05211813